FindMyKOL
Clinical trialNCT07604662Not, yet, recruitingInterventional

Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial

NCT07604662 is an interventional trial sponsored by University of California, San Francisco. As of 18 Nov 2026, it is not yet recruiting. It studies Acute Kidney Injury, Anesthesia and 1 more condition. The registry lists an enrollment of 25,518 participants at 1 site in 1 country. The registry lists a start date of 15 Oct 2026 and a primary completion date of 15 Oct 2027.

SponsorUniversity of California, San Francisco →Enrollment25,518Acute Kidney InjuryAnesthesiaSurgery Complications
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07604662
FieldValue
Registry IDNCT07604662
StatusNot yet recruiting
Study typeInterventional trial
Lead sponsorUniversity of California, San Francisco
Enrollment25,518
Registered sites1
Countries1
ConditionsAcute Kidney Injury, Anesthesia and Surgery Complications
Start15 Oct 2026
Primary completion15 Oct 2027
Study completion15 Dec 2027
Last update posted22 May 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best/Our Practice Advisory (BPA/OPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs/residents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL/min/1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg/dL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • University of California, San Francisco

    San Francisco

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT07604662

Each answer restates registry values shown on this page.

What is NCT07604662?

NCT07604662 is an interventional trial sponsored by University of California, San Francisco. It studies Acute Kidney Injury, Anesthesia and 1 more condition.

Is NCT07604662 recruiting?

As of 18 Nov 2026, it is not yet recruiting.

Who leads NCT07604662?

The registry names Andrew Bishara, MD (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT07604662 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT07604662 expected to complete?

The registry lists a primary completion date of 15 Oct 2027 and a study completion date of 15 Dec 2027. The sponsor last updated the record on 22 May 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.